Primary Leptomeningeal B-cell Lymphoma in an Immunocompetent Adult: Case Report

Andrea Calderon-Castro1, Leonardo Enciso2,3, Rafael Tejada-Cabrera4

  • 1Neurology, Hospital Universitario Nacional de Colombia, Bogotá, COL.

Cureus
|December 27, 2021
PubMed

Insights

Primary leptomeningeal lymphoma (PLML) is a rare cancer affecting the brain and spinal cord lining. Early diagnosis and treatment with high-dose methotrexate and rituximab can significantly improve patient outcomes.

Area of Science:

  • Neurology
  • Oncology
  • Hematology

Background:

  • Primary leptomeningeal lymphoma (PLML) is a rare neoplastic condition, accounting for less than 1% of all lymphomas.
  • Clinical symptoms include headache, encephalopathy, ataxia, cranial nerve palsy, and myelitis, often necessitating extensive diagnostic workup.

Observation:

  • A 49-year-old male presented with subacute headache, encephalopathy, and blindness.
  • Systemic lymphoma was excluded via whole-body examinations and bone marrow biopsy.
  • Brain MRI revealed leptomeningeal enhancement, and CSF analysis identified a clonal B-cell population, confirming PLML.

Findings:

  • Treatment initiated with rituximab and high-dose methotrexate (HD-MTX) resulted in progressive clinical improvement.
  • Post-treatment CSF analysis and imaging demonstrated normalization of findings after two cycles of therapy and one intrathecal methotrexate dose.

Implications:

  • Accurate diagnosis of PLML requires integrating MRI, CSF cytology, flow cytometry, and exclusion of systemic disease.
  • Early therapeutic intervention utilizing HD-MTX, with or without rituximab, is associated with improved clinical outcomes in PLML patients.